Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2023 Feb 20.

Published in final edited form as: Clin Cancer Res. 2022 Jun 13;28(12):2567–2578. doi: 10.1158/1078-0432.CCR-21-4064

Figure 1. — Efficacy for all patients including Kaplan-Meier plots and tabular PFS and OS data by cohort. Outcome for newly diagnosed, MGMT unmethylated patients (cohort A), bevacizumab naïve, recurrent patients (cohorts B, B2 and B3) and bevacizumab refractory, recurrent patients (cohort C) are summarized in panels A, B and C, respectively including Kaplan-Meier plots of PFS (upper) and OS (lower).

Figure 1. — Efficacy for all patients including Kaplan-Meier plots and tabular PFS and OS data by cohort. Outcome for newly diagnosed, MGMT unmethylated patients (cohort A), bevacizumab naïve, recurrent patients (cohorts B, B2 and B3) and bevacizumab refractory, recurrent patients (cohort C) are summarized in panels A, B and C, respectively including Kaplan-Meier plots of PFS (upper) and OS (lower).